Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

In order to support the safe and efficient use of JAK inhibitors in the treatment of patients, an international panel of experts has published new guidelines. Janus kinase inhibitors (JAKis ...

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Patients with atopic dermatitis (AD) who were treated with Janus kinase (JAK ... with AD receiving immune-modulating drugs. The JAK and Th2 cytokine inhibitor cohorts comprised 54.8% and 54.2 ...

Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.